Unique ID issued by UMIN | UMIN000010517 |
---|---|
Receipt number | R000012276 |
Scientific Title | Interfractional displacement and variation of prostate during multifractionated high-dose-rate interstitial brachytherapy |
Date of disclosure of the study information | 2013/04/19 |
Last modified on | 2018/05/05 17:12:15 |
Interfractional displacement and variation of prostate during multifractionated high-dose-rate interstitial brachytherapy
Interfractional displacement and variation of prostate during multifractionated high-dose-rate interstitial brachytherapy
Interfractional displacement and variation of prostate during multifractionated high-dose-rate interstitial brachytherapy
Interfractional displacement and variation of prostate during multifractionated high-dose-rate interstitial brachytherapy
Japan |
prostate cancer
Radiology |
Malignancy
NO
The aim of this study is to measure prostate displacement and valiation during the treatment of high dose rate interstitial brachytherapy by CT, and to establish the best optimization protocol.
Safety,Efficacy
Confirmatory
Explanatory
Not applicable
The displacement measurement of the applicator for the marker in the prostate during the prostatic monotherapy period.
Evaluation of the change of DVH of OAR and CTV with the displacement.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Measure the displacement of needle applicator according to the gold marker inserted in prostate by CT during high dose rate interstitial monothreapy treatment period
20 | years-old | <= |
80 | years-old | >= |
Male
*Histologically proven prostate cancer
*Any Gleason Score
*Any pretreatment PSA
*Any T stage
*Clinicaly diagnosed as N0M0 with MRI, bone scan, CT and so on.
*Use UICC TNM2009 for staging.
*ECOG performance status 0 or 1.
*Blood test results are compatible with criterias as below.
WBC>=3000/ul, Hb>=10.0g/dl, Plt>=100000/ul, Cre>=2.0 mg/dl, GOT>=100U/L, GPT<=100U/L
*Without any history of local therapy such as operation, trans-urethral procedure, hyperthermia. Hormonal therapy is permitted.
*Informed concented cases.
*Case having an active synchronous double cancer.
*Case having an uncontrollable diabetes .
*Case having a complication that doesn't quit internal use of anticoagulant.
*Case having a serious cranial nerve disease
*Case having collagenosis
*The case that the examination medical attendant judged to be inappropriate
20
1st name | |
Middle name | |
Last name | Yasuo Yoshioka |
Osaka University Graduate School of Medicine
Radiation Oncology
2-2 D10, Yamadaoka, Suita
06-6879-3482
yoshioka@radonc.med.osaka-u.ac.jp
1st name | |
Middle name | |
Last name | Osamu Suzuki |
Osaka University Graduate School of Medicine
Radiation Oncology
2-2 D10, Yamadaoka, Suita
06-6879-3482
osamu-s@umin.ac.jp
Osaka University Graduate School of Medicine, Dept of Radiation Oncology
none
Self funding
none
none
none
NO
大阪大学医学部附属病院
2013 | Year | 04 | Month | 19 | Day |
Unpublished
Enrolling by invitation
2013 | Year | 04 | Month | 11 | Day |
2013 | Year | 04 | Month | 22 | Day |
2015 | Year | 03 | Month | 31 | Day |
2015 | Year | 01 | Month | 31 | Day |
2015 | Year | 03 | Month | 31 | Day |
2013 | Year | 04 | Month | 17 | Day |
2018 | Year | 05 | Month | 05 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012276